Regencell Bioscience (NASDAQ:RGC) Stock Price Up 32% - Should You Buy?

Key Points

• Shares jumped 32% intraday to $33.57 from a prior close of $25.43 on Wednesday, with about 202,455 shares traded—roughly half the stock's average daily volume.
• Analyst sentiment is negative: Weiss Ratings reiterated a "sell (e+)" and MarketBeat's average rating for RGC is "Sell".
• Company and ownership note: Regencell develops Traditional Chinese medicine treatments for neurocognitive disorders (ADHD, autism), and institutional ownership is very low at about 0.13% despite a few recent small hedge fund stakes.

Shares of Regencell Bioscience Holdings Limited (NASDAQ:RGC - Get Free Report) were up 32% during trading on Wednesday . The company traded as high as $33.00 and last traded at $33.5680. Approximately 202,455 shares were traded during trading, a decline of 50% from the average daily volume of 405,187 shares. The stock had previously closed at $25.43.

Analyst Ratings Changes

Separately, Weiss Ratings restated a "sell (e+)" rating on shares of Regencell Bioscience in a research note on Friday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of "Sell".

Regencell Bioscience Stock Up 44.1%

The company's 50 day simple moving average is $26.86 and its 200 day simple moving average is $21.58.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Seven Fleet Capital Management LP purchased a new stake in Regencell Bioscience in the fourth quarter valued at $92,000. Vident Advisory LLC increased its position in shares of Regencell Bioscience by 65.7% during the fourth quarter. Vident Advisory LLC now owns 29,934 shares of the company's stock worth $629,000 after purchasing an additional 11,866 shares in the last quarter. Hudson Bay Capital Management LP acquired a new stake in shares of Regencell Bioscience during the fourth quarter worth about $275,000. XTX Topco Ltd purchased a new stake in shares of Regencell Bioscience in the 3rd quarter valued at about $598,000. Finally, BNP Paribas Financial Markets purchased a new stake in shares of Regencell Bioscience in the 2nd quarter valued at about $768,000. 0.13% of the stock is owned by hedge funds and other institutional investors.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.